Ascendis Pharma Reports Durable Growth in Achondroplasia Combination Therapy, YUVIWEL Launch Traction
ASND sits 43% above its 52-week low of $175.19 on light trading volume (0.2× avg).
Summary
Ascendis Pharma reported durable Week 78 combination therapy data in achondroplasia and early commercial traction for YUVIWEL, reinforcing its leadership in the space.
Key Events · Product Development and Regulatory · ASND
-
Combination Therapy Shows Durable Growth
Week 78 COACH trial data: mean AGV of 7.73 cm/year (naïve) and 7.67 cm/year (experienced), at or above 97th percentile for average-stature children, with 100% retention and no new safety signals.
-
Monotherapy Benefits Beyond Height
Week 104 ApproaCH data confirmed durable height improvements and benefits in limb alignment and body proportionality; 96% of 140 children remain on therapy in long-term extension.
-
YUVIWEL Launch Gains Traction
Over 170 unique patient enrollments by ~90 prescribers through June 30, 2026, with more than 65% approved for reimbursement — all new to therapy.
-
EU Regulatory Decision Expected Q4 2026
Marketing Authorisation Application for TransCon CNP monotherapy in achondroplasia under review; decision anticipated in the fourth quarter of 2026.
Analysis · ASND · Life Sciences
Ascendis Pharma disclosed positive Week 78 data from its COACH trial showing that the combination of TransCon CNP and TransCon hGH sustained growth at or above the 97th percentile for children of average stature, with no safety concerns and 100% retention. The company also provided a commercial update for YUVIWEL (TransCon CNP monotherapy) with over 170 patient enrollments and strong reimbursement approval, signaling early market acceptance. These results strengthen the case for a best-in-class achondroplasia franchise and come ahead of an anticipated EU regulatory decision in Q4 2026.
How filings like this one have moved
In the 30 days to Oct 11, 2026, 36.1% of the 1010 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASND was trading at $250.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.6B. The 52-week trading range was $175.19 to $282.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.